A bifunctional chiral agent (BCA) strategy opens a new window to develop essential enantiomerically pure pharmaceutical products. In their Communication (e202402886), Weiwei Tang et al. report a novel crystallization-induced deracemization method using BCA that demonstrates the dual functions of cocrystallization and catalytic racemization. This BCA strategy could address the incompatibility between cocrystallization and racemization reaction conditions.
No takes yet. Share an insight, caveat, or question.
Su et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: